Marketing-authorisation holder
Oncopeptides Ab
3 medicines in 3 countries, as authorisation holder and marketer.
Medicines
Every medicine in the registers under its name, current ones first.
3 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| PEPAXTIPolvere per concentrato e soluzione per soluzione per infusione | Melphalan flufenamide | Italy | Authorised | |
| Pepaxti 20 mg, poeder voor concentraat voor oplossing voor infusiePoeder voor concentraat voor oplossing voor infusie | Melphalan flufenamide | Netherlands | Authorised | 2022 |
| PEPAXTI 20 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION21,48 mg · Polvo para concentrado para solución para perfusión | Melphalan flufenamide | Spain | Marketed | 2023 |
Countries
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Spain | 1 | 1 | 0 | CompaniesAll medicines |
| Italy | 1 | 1 | 0 | CompaniesAll medicines |
| Netherlands | 1 | 1 | 0 | CompaniesAll medicines |
Also in the registers of United Kingdom
Therapeutic areas
The ATC groups most of its medicines belong to, largest first.
- Antineoplastic agentsAntineoplastic and immunomodulating agents · ATC L01A
Top substances
The active substances in most of its medicines.
Names in the registers
How the registers spell it, normalised: legal forms, accents and capitals removed.
- oncopeptides
Sources and licences
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
At a glance
- Type
- Marketing-authorisation holder
- Medicines
- 3
- Countries
- 3
- Roles
- Authorisation holder and marketer